耐甲氧西林金黄色葡萄球菌致下呼吸道医院感染的治疗效果分析  

Study on clinical therapeutic effects of lower respiratory tract nosocomical infections caused by MRSA

作　　者：何晓锋[1] 曹晋桂[1] 张虎[1] 刘芳[1] 崔霞[1] 吴镝[1] 马文杰[1] 

机构地区：[1]空军总医院感染控制科,北京100142

出　　处：《空军医学杂志》2013年第2期105-106,113,共3页Medical Journal of Air Force

摘　　要：目的了解抗菌药物对耐甲氧西林金黄色葡萄球菌(MRSA)引起的下呼吸道医院感染的治疗效果,并比较万古霉素与替考拉宁的疗效差异。方法对64例MRSA所致医院获得性下呼吸道感染病例进行回顾性分析,并采用病例对照研究方法比较34例万古霉素治疗患者和30例替考拉宁治疗患者的疗效。结果使用万古霉素和替考拉宁治疗的共计64例患者有效率为70.3%,万古霉素组的疗程、有效率和MRSA清除率分别为11.1 d、65.6%和61.8%,替考拉宁组分别为12.1 d、76.7%和70.0%,两组比较均无统计学差异。结论万古霉素、和替考拉宁胺都可用于治疗MRSA引起的下呼吸道医院感染且治疗效果无差异。Objective We aimed to investigate the therapeutic effect of antimicrobial agents for lower respiratory tract nosocomical infections caused by Methicillin-resistant Staphylococcus aureus（MRSA）,and compare the clinical effects between vancomycin and teicoplanin。 Methods All 64 cases of lower respiratory tract nosocomical infections caused by MRSA who were treated in our hospital were analyzed retrospectively.The differences of the clinical effects of 34 cases with vancomycin therapy and 30 cases with teicoplanin were compared.Results The effective rate of all 64 cases treated with vancomycin,teicoplanin and linezolid was 70.3%.The length of stay,effective rate and MRSA clearance rate between vancomycin group and teicoplanin group had no statistically significance,with 11.1 days,65.6% and 61.8% in the former,12.1 days,76.7% and 70.0% in the latter.Conclusions Vancomycin,teicoplanin and linezolid could be used to treat lower respiratory tract infection caused by MRSA.Both vancomycin and teicoplanin exhibited a similar clinical efficacy.

关 键 词：耐药 金黄色葡萄球菌 万古霉素 替考拉宁 

分 类 号：R978.1[医药卫生—药品]